03/06/2026
ISPOR responded to the European Medicines Agency (EMA) consultation on the Patient Experience Data Reflection Paper. We support the Agency’s leadership in advancing patient-centered approaches and highlight opportunities to strengthen decision relevance, early and systematic integration, methodological clarity, transparency, and alignment with existing guidance. Read ISPOR's response here: https://ow.ly/r7Lg50Ypb6J